RIGL Q4 2024 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$541M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$58M+60.9% YoY

Gross Profit

$52M89.9% margin

Operating Income

$17M28.9% margin

Net Income

$14M24.9% margin

EPS (Diluted)

$0.80

QoQ Revenue Growth

+4.1%

Cash Flow

Operating Cash Flow

$15M

Free Cash Flow

$14M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$164M

Total Liabilities

$161M

Stockholders' Equity

$3M

Cash & Equivalents

$57M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$58M	$36M	+60.9%
Gross Profit	$52M	$32M	+61.9%
Operating Income	$17M	$2M	+747.2%
Net Income	$14M	$737,000	+1845.9%

Revenue Segments

Gross product sales

$115M58%

Product sales, net

$80M40%

License

$4M2%